English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsTriveniturbine

    Jump to
    • Will end the year with 25% growth: Thyrocare

      Will end the year with 25% growth: Thyrocare

      Overbilling is not a simple game, it is a serious calculation, said A Velumani, Chairman, CEO and Managing Director of Thyrocare Technologies.

    • Would look to add 4 more regional processing labs, says Thyrocare

      Would look to add 4 more regional processing labs, says Thyrocare

      Thyrocare Technologies posted a good set of numbers this quarter. In an interview to CNBC-TV18, A Velumani, Chairman, MD & CEO of Thyrocare Technologies discussed the company's Q1 performance.

    • Wellness segment contributes majority of growth: Thyrocare's Velumani

      Wellness segment contributes majority of growth: Thyrocare's Velumani

      In an interview to CNBC-TV18, A Velumani, Chairman, CEO & MD of Thyrocare Technologies spoke about the results and his outlook for the company.

    • Aim to sustain 25% topline growth in FY17: Thyrocare

      Aim to sustain 25% topline growth in FY17: Thyrocare

      Thyrocare Technologies is betting big on the radiology vertical which requires huge capex, but is capable of bringing in good business, says Chairman, CEO & MD A Velumani.

    • Thyrocare chief sees a sales growth of 25% in third quarter

      Thyrocare chief sees a sales growth of 25% in third quarter

      Diagnostics company Thyrocare Technologies felt the blow of demonetisation in the month of November but was back on its feet and saw growth at 24 percent in the month under review.

    • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

      Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

      USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

    • Thyrocare hopeful of growing revenues 25% in FY17

      Thyrocare hopeful of growing revenues 25% in FY17

      Thyrocare‘s revenue grew 21.7 percent to Rs 69.36 crore and operating profit margins improved to 39.4 percent in the first quarter of FY17.

    • Can sustain margins at 40%; a regulator is welcome: Thyrocare

      Can sustain margins at 40%; a regulator is welcome: Thyrocare

      A regulatory body for labs could help the unorganised sector as well as help mitigate risks for companies, says A Velumani, Chairman, CEO & MD of the company.

    • To start 25 centres in next 36-48 months: Thyrocare

      To start 25 centres in next 36-48 months: Thyrocare

      The newly listed Thyrocare Technologies aims to maintain the revenue growth of 30 percent in FY17, says the CEO and CMD A Velumani, in an exclusive interview with CNBC-TV18.

    • No revenue-share agreement with doctors, clarifies Thyrocare

      No revenue-share agreement with doctors, clarifies Thyrocare

      Thyrocare neither has any revenue share agreement with doctors nor does it pay them any commissions to send patients to their laboratories, says CMD A Velumani.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347